ETNB

89bio (ETNB)

About 89bio (ETNB)

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Details

Daily high

$8.19

Daily low

$7.71

Price at open

$7.72

52 Week High

$16.63

52 Week Low

$6.58

Market cap

825.0M

Dividend yield

0.00%

Volume

168,448

Avg. volume

627,626

P/E ratio

-3.95

89bio News